SAN DIEGO--(BUSINESS WIRE)--Orexigen™ Therapeutics, Inc. (Nasdaq: OREX) announced today the that its underwriters partially exercised their overallotment option to purchase an additional 326,435 shares of its common stock in connection with its previously announced public offering that priced on January 23, 2008. Including the overallotment shares purchased, the company sold 7,326,435 shares at a public offering price of $11.00 per share, resulting in expected net proceeds to the company of approximately $75.8 million (after payment of the underwriting discount, but excluding estimated offering expenses).
